Clinical Trials Logo

Reperfusion Injury clinical trials

View clinical trials related to Reperfusion Injury.

Filter by:

NCT ID: NCT01223326 Completed - Hepatectomy Clinical Trials

N-acetylcysteine to Reduce Ischemia/Reperfusion Injury in Liver Resection

Start date: January 2003
Phase: Phase 4
Study type: Interventional

Study hypothesis: N-acetylcysteine (NAC) can reduce ischemia/reperfusion injury in liver resection performed under ischemic preconditioning and intermittent portal triad clamping.

NCT ID: NCT01208727 Completed - Clinical trials for Myocardial Reperfusion Injury

Post Cond No Reflow

Start date: April 2009
Phase: N/A
Study type: Interventional

After having shown that postconditioning allowed a significant 36% reduction of infarct size as assessed by blood levels of myocardial enzymes in acute myocardial patients, the investigators objective is to assess the effect of postconditioning in acute myocardial infarction (AMI) patients on microvascular obstruction lesions defined by cardiac MRI images.

NCT ID: NCT01172691 Active, not recruiting - Liver Transplant Clinical Trials

Trial of Inhaled Nitric Oxide (iNO) on Ischemia / Reperfusion Injury During Orthotopic Liver Transplantation With Marginal Grafts

Start date: July 2010
Phase: Phase 2
Study type: Interventional

This study is being done to determine if patients receiving (iNO) will have increased liver function and less damage from IR than patients who do not receive (iNO).

NCT ID: NCT01172171 Completed - Clinical trials for Acute Myocardial Infarction

The Effect of Melatonin on Ischemia-reperfusion Injury Following Acute Myocardial Infarction

Start date: June 2013
Phase: Phase 2
Study type: Interventional

In Denmark, 12.000 people a year, is struck by acute myocardial infarction. A third of these cannot be saved before treatment is possible. Despite quick and effective reperfusion of the coronary arteries using PCI (Percutaneous Coronary Intervention) after an acute ST-elevation myocardial infarction, substantial morbidity and mortality remain. Infarct size is an important determinant of the short-and long-term outcome after acute myocardial infarction. The most widely used and most effective proven therapy to limit infarct size is the early reperfusion induced by or PCI. Although beneficial in terms of myocardial salvage, reperfusion itself may contribute to additional damage of the myocardium; the damage due to the combined processes is known as "ischemia-reperfusion injury". The pathogenesis of myocardial ischemia-reperfusion injury is a multifactorial process involving the interaction of multiple mechanisms. Numerous studies indicate that there are three pivotal factors in the pathogenesis of ischemia-reperfusion injury: elevated oxidative damage, depressed energy metabolism, and altered calcium homeostasis. Partially reduced species of oxygen, including the superoxide anion radical, hydroxyl radical, and hydrogen peroxide, are generated intracellularly as by-product of oxygen metabolism. These reactive oxygen species cause peroxidation af membrane lipids, denaturation of proteins, and modification of DNA, all of which ultimately can lead to cell death. In mammals, cell damage induced by partially reduced oxygen species can also initiate local inflammatory responses, which then lead to further oxidant-mediated tissue injury. Melatonin is mainly known for its role as an endogenously produced circadian hormone. For the last twenty years, increasing evidence has proven melatonin to be a very potent direct and indirect antioxidant. Recent experimental studies have documented the beneficial effects of melatonin in reducing tissue damage and limiting cardiac pathophysiology in models of experimental ischemia-reperfusion. Primary hypothesis: Melatonin given to patients undergoing PCI can reduce the myocardial damage sustained by ischemia-reperfusion.

NCT ID: NCT01167569 Completed - Reperfusion Injury Clinical Trials

Study of High Dose Vitamin C On Outcome in Cardiac Surgery Patients

VitaminC
Start date: October 2007
Phase: Phase 4
Study type: Interventional

It has been shown that the stress that occurs during cardiac surgery leads to early decrease of many of the body's resources such as Vitamin C (ascorbic acid) which may contribute to complications after surgery. This study will investigate the effects of high doses of intravenous (IV) Vitamin C on the outcome and complications after cardiac surgery.

NCT ID: NCT01149993 Withdrawn - Clinical trials for Kidney Transplantation

Attenuating Ischemia Reperfusion Injury After Living Donor Renal Transplantation

Start date: June 2010
Phase: Phase 4
Study type: Interventional

Patients undergoing living donor renal transplant will be asked to participate to determine whether pre-operative dosing of immunosuppressive medication, and the donor organ receiving an additional dose of antibody induction therapy helps to alleviate potential damage to the transplanted organ post-transplant. A number of lab tests will be done post-transplant to determine how well the kidney is functioning.

NCT ID: NCT01144585 Completed - Acute Lung Injury Clinical Trials

Effects of Remote Ischemic Preconditioning and Postconditioning on Lung Injury During Cardiopulmonary Bypass

Start date: May 2010
Phase: N/A
Study type: Interventional

Remote Ischemic Preconditioning(RIPC) and remote ischemic postconditioning(RIPoC) seems to have a protective effect during ischemic period. Using cardiopulmonary bypass(CPB) during open heart surgery reduces pulmonary blood flow and may cause ischemic damage to lung tissue. The investigators anticipate that RIPC and RIPoC may reduce lung injury after CPB.

NCT ID: NCT01120769 Withdrawn - Clinical trials for Acute Myocardial Infarction

Acetaminophen to Prevent Ischemic Oxidative Reperfusion Injury During Percutaneous Coronary Intervention for Acute Myocardial Infarction

APRIORI Pilot
Start date: July 2011
Phase: N/A
Study type: Interventional

The purpose of this study is to test the hypothesis that acetaminophen will reduce lipid peroxidation and isoprostane formation during reperfusion after percutaneous revascularization for acute myocardial infarction.

NCT ID: NCT01113008 Completed - Clinical trials for Myocardial Reperfusion Injury

Remote Ischemic Postconditioning in Humans

Start date: February 2009
Phase: N/A
Study type: Interventional

The aim of this study is to evaluate the phenomenon of remote ischemic post-conditioning in humans. The minor myocardial damage associated with percutaneous revascularization procedures may be attenuated by producing controlled ischemia in the arms immediately after carrying out these procedures (remote ischemic post-conditioning). The justification and design of this clinical trial has been reported: Cardiology. 2011;119(3):164-9.

NCT ID: NCT01073202 Completed - Clinical trials for Liver Transplantation

Effects of Ursodeoxycholic Acid on Graft Recovery Early After Adult Liver Transplantation

Start date: May 2005
Phase: N/A
Study type: Interventional

This study is designed to investigate the possible beneficial effects of UDCA on liver graft recovery early after adult liver transplantation.